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RIG-I is a viral RNA sensor that induces the production of type I interferon (IFN) in response
to infection with a variety of viruses. Modiﬁcation of RIG-I with K63-linked poly-ubiquitin
chains, synthesised by TRIM25, is crucial for activation of the RIG-I/MAVS signalling path-
way. TRIM25 activity is targeted by inﬂuenza A virus non-structural protein 1 (NS1) to
suppress IFN production and prevent an efﬁcient host immune response. Here we present
structures of the human TRIM25 coiled-coil-PRYSPRY module and of complexes between the
TRIM25 coiled-coil domain and NS1. These structures show that binding of NS1 interferes
with the correct positioning of the PRYSPRY domain of TRIM25 required for substrate ubi-
quitination and provide a mechanistic explanation for how NS1 suppresses RIG-I ubiquiti-
nation and hence downstream signalling. In contrast, the formation of unanchored K63-linked
poly-ubiquitin chains is unchanged by NS1 binding, indicating that RING dimerisation of
TRIM25 is not affected by NS1.
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S ignalling pathways mediating innate immune responses areregulated by multiple post-translational modiﬁcations toallow for a dynamic and speciﬁc host response to infection.
One of these is ubiquitination, where target proteins are tagged
with poly-ubiquitin chains to alter their behaviour and for
example change their stability, activity or promote the formation
of protein–protein complexes. Ubiquitination is catalysed by E3
ubiquitin ligases that transfer ubiquitin to a lysine side chain of
the target and build poly-ubiquitin chains1. Tripartite motif
(TRIM) family proteins are RING-type E3 ligases that play key
regulatory roles in innate immune signalling pathways that lead
to the induction of a type I interferon (IFN) response and pro-
duction of inﬂammatory cytokines through activation of the IRF3
and NF-κB transcription factors2,3. Members of the TRIM family
are characterised by a conserved domain architecture that
includes an N-terminally located TRIM comprising a catalytic
RING domain, one or two B-box domains and a coiled-coil (CC)
domain that mediates dimerisation4–6 (Fig. 1a). The C-terminal
region of TRIMs contains non-catalytic domains, which often
recognise E3 ligase substrates and other targets.
Infection of host cells with viral pathogens is sensed by pattern
recognition receptors (PRRs) that trigger an antiviral response.
RIG-I is a member of the RIG-I-like receptor (RLR) family of
PRRs that reside in an auto-inhibited state in uninfected cells in
which the N-terminal tandem CARDs (caspase activation and
recruitment domains) are unavailable for signalling7,8. Activation
of RIG-I initiates a signalling cascade that depends on the E3
ligase activity of TRIM25 and induces the production of IFNs and
inﬂammatory cytokines. Interaction with viral RNA and ATP
releases the auto-inhibited conformation of RIG-I thereby
allowing K63-linked poly-ubiquitination of its second CARD by
TRIM25 (Fig. 1a)8–12. RIG-I ubiquitination in turn promotes its
oligomerization into a helical assembly, enabling interaction with
the downstream effector MAVS (mitochondrial antiviral signal-
ling) and formation of ﬁlamentous structures that activate a
signalling cascade culminating in the production of IFN-α/β13,14.
Additional K63-linked ubiquitination of RIG-I is mediated by the
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Fig. 1 Oligomeric state of NS1 and identiﬁcation of TRIM25-interacting domains. a Schematic representation of TRIM25, NS1 and RIG-I domain structures.
The crystallised TRIM25 CC-PRYSPRY domain is highlighted in blue and the crystallised RBD and NS1 domains of NS1 in red. The tandem CARD construct
of RIG-I used in substrate ubiquitination assays is highlighted in purple. b The effect of different mutations on the oligomeric state of NS1-FL assessed by
SEC–MALLS. The traces are colour coded according to the NS1 mutant and concentration used. c Quantiﬁcation of the TRIM25-CC interaction with NS1 by
biolayer interferometry (BLI). The binding curves are colour-coded and Kds determined are listed. The error is the standard deviation (s.d.) of mean from at
least three independent experiments
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E3 ligase Riplet and possibly other E3 ligases, though the precise
interplay between TRIM25, Riplet and other E3s and their
respective contribution to the activation of RIG-I is not fully
understood15–18. In addition to direct ubiquitination of RIG-I,
biochemical experiments have suggested that unanchored K63-
linked poly-ubiquitin chains can also activate the RIG-I/MAVS
signalling pathway19. Structural studies have shown that these
chains wrap around the tandem CARDs of RIG-I and form a
helical assembly that acts as a seed for MAVS ﬁlament forma-
tion20. Importantly, regardless of the covalent or non-covalent
nature of the K63-linked poly-ubiquitin chains involved, the
catalytic activity of TRIM25 is crucial for their synthesis and IFN-
β promoter activation21.
Substrate recognition is mediated by the C-terminal PRYSPRY
(also known as B30.2) domain of TRIM25, which recognises
CARD1 of RIG-I to promote ubiquitination of K172 in
CARD211,22. Catalytic activity of TRIM25 requires dimerisation
of its RING domains, which may occur in an intramolecular
fashion23, and be enhanced by the PRYSPRY/RIG-I tandem
CARD interaction21. At present no structures of full-length
TRIMs are available and it is not known how the E2-Ub-binding
RING domains and the substrate are brought into close proximity
to mediate ubiquitin transfer. First insight into the relative
position of a PRYSPRY domain with respect to the CC came from
the structural characterisation of the TRIM20 CC-PRYSPRY
fragment, which showed that the PRYSPRY can adopt multiple
positions around the centre portion of the anti-parallel CC
dimer24.
Pathogenic viruses have evolved a variety of mechanisms to
inhibit the RIG-I signalling pathway and suppress the host innate
immune response25,26. An example is non-structural protein 1
(NS1) of inﬂuenza A viruses (IAV), a multifunctional virulence
factor that binds many host proteins during infection, including
TRIM2527–29. NS1 is composed of an RNA-binding domain
(RBD, a.a. 1–73) followed by a short linker to the effector domain
(ED, a.a. 85–202) and an unstructured C-terminal tail (Fig. 1a).
Multiple structures of individual domains and two structures of
full-length NS1 have provided insight into self-association of NS1,
conformational ﬂexibility of the RBD and ED architecture and
the interaction with dsRNA and host proteins28–31. However,
many questions remain, especially regarding the link between the
oligomeric state of NS1 and its function. NS1 is a constitutive
homodimer, mediated by a high afﬁnity interaction between the
RBDs, but forms concentration-dependent higher order oligo-
mers due to weak interactions between EDs via a surface invol-
ving W187 and possibly between RBDs32–34. Such higher order
self-association may be important for some of its functions, such
as dsRNA binding35.
The mechanistic details underlying NS1-mediated inhibition of
TRIM25 are not fully understood at present and while an earlier
report showed that NS1 binding directly interferes with the E3
ligase activity of TRIM2527, a recent study suggests that NS1
antagonises binding of TRIM25 to viral ribonucleoprotein par-
ticles (vRNPs) thus inhibiting RNA synthesis, an E3 ligase
independent activity36.
To elucidate the mechanism of NS1-mediated suppression of
TRIM25 activity we have determined the crystal structures of
complexes between the CC of TRIM25 bound to NS1-FL and the
isolated ED and characterised their interaction biochemically. To
the best of our knowledge, this is the ﬁrst structure of full-length
NS1 bound to a target protein and provides insight into the
architecture of NS1-host protein complexes. Our data show that
CC-mediated dimerisation of TRIM25 is unperturbed in these
complexes, as is its ability to synthesise unanchored K63-linked
poly-ubiquitin chains. Instead, a comparison with the structure of
a TRIM25 CC-PRYSPRY fragment, also reported here, shows that
NS1 binding displaces the PRYSPRY domain from the CC,
thereby preventing RIG-I ubiquitination. Furthermore, our study
suggests that the ability of NS1 to self-associate into higher order
oligomers and crosslink different molecules of TRIM25, is
important for NS1 function.
Results
The ED of NS1 forms a stable complex with TRIM25. The
interaction between TRIM25 and NS1 has been suggested to
require both the RBD and ED of NS1, while the region in
TRIM25 recognising NS1 has been mapped to the CC domain27
(Fig. 1a). To further characterise complex formation we aimed to
quantitate the interaction using puriﬁed full-length NS1 (NS1-FL)
of strain A/Puerto Rico/8/1934 H1N1 (hereafter referred to as
NS1) and the coiled-coil domain of TRIM25 (TRIM25-CC)27.
Unfortunately, wild-type NS1-FL aggregates even at low con-
centrations. Consequently, past structural studies were carried out
on constructs containing two mutations (R38A/K41A) that lar-
gely suppress aggregation (Fig. 1b) and this allowed structure
determination of full-length NS129,30. However, these mutations
were reported to prevent interaction with TRIM25-CC27.
Therefore, we attempted to identify novel NS1-FL constructs with
improved solubility. Consistent with previous observations32,
mutation of W187A in the ED greatly improves protein solubility
of NS1 and SEC–MALLS analysis shows it is mainly dimeric with
some minor propensity to form concentration-dependent oligo-
mers (Fig. 1b). In contrast, a triple mutant protein (R38A/K41A/
W187A) is strictly dimeric in solution (Fig. 1b). The ability of
these proteins to interact with TRIM25 was investigated by bio-
layer interferometry (BLI). NS1 W187A bound TRIM25-CC with
an afﬁnity of 12.5 µM, which was not reduced in the triple mutant
(8.2 µM) (Fig.1c). In light of this observation, we tested binding of
individual NS1-RBD and NS1-ED to TRIM25-CC. These
experiments showed that the ED alone binds TRIM25-CC with
an afﬁnity of 16.1 µM, whereas no binding could be detected with
the RBD alone at concentrations up to 300 µM (Fig. 1c). In
conclusion, these experiments establish that the effector domain
of NS1 is sufﬁcient to form a stable complex with the coiled-coil
domain of TRIM25.
Structure of the core NS1-ED/TRIM25-CC complex. To gain
molecular insight into the interaction between NS1 and TRIM25
we determined the crystal structure of the NS1-ED/TRIM25-CC
complex at 2.8 Å resolution by molecular replacement (R/Rfree=
0.20/0.22) (Table 1 and Supplementary Fig.1a). The complex
crystallised in space group C222 with three copies of each NS1-
ED and TRIM25-CC monomer in the asymmetric unit (Fig. 2a).
Symmetry analysis shows that each NS1-ED binds to a TRIM25-
CC dimer via two separate interfaces, interface A and interface B,
which bury 872 and 611 Å2, respectively, of solvent accessible
surface (Fig. 2b). Complex formation between TRIM25-CC
and NS1-ED does not induce major conformational changes in
either protein and the structures of the bound and unbound
domains overlap with RMSD values of 2.41 Å (for 156 residues)
for TRIM25-CC (PDB:4LTB) and 0.56 Å (for 117 residues)
for NS1-ED and apo-NS1-ED (PDB:3O9T) (Supplementary
Fig. 1b–d)32,37. The biggest difference between apo TRIM25-CC
and the NS1-bound state is seen in the linker connecting helix α2
to the central helix α3, which is pushed from its position in the
apo TRIM25-CC structure towards helix α1 due to contacts by
NS1-ED from interface A. This copy of NS1-ED makes contacts
with both TRIM25 chains within the CC dimer via a highly
conserved motif of NS1 that includes a short α helix comprising
residues 95–99 (Fig. 2c). Previous mutational analysis identiﬁed
E96 and E97 in this motif as crucial for TRIM25 binding and
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inhibition of interferon production27. Our structure now shows
that the side chains of E96 and E97 point away from the binding
interface with TRIM25. However, they form a network of con-
tacts within NS1-ED, especially between the side chains of E96
and R100, which is likely important to maintain the structural
integrity of this helix (Fig. 2c). Instead, L95ED of this helix is a key
element of the interface and contacts a hydrophobic pocket of
TRIM25 formed by residues from both chains of the CC
including V223CC, F274CC, I277CC, I324CC and V327CC. This
interaction is further stabilised by a hydrogen bond between the
backbone of L95ED and the side chain of E326CC. Additional
interactions between NS1-ED and one of the CC monomers
involve Y89ED, which forms hydrogen bonds with D222CC and
D229CC, and between E101ED and Q212CC. (Fig. 2c). Interface B
involves loop-forming NS1-ED residues 139-143 that contact the
central four-helical bundle of TRIM25-CC with R140ED at its
centre (Fig. 2d). To investigate the relative importance of either
interface in solution we measured binding of ED constructs
containing mutations L95AED/S99AED or R140AED to TRIM25-
CC by BLI. These experiments showed that R140AED still binds
with 24.1 µM afﬁnity (Fig. 1c, orange circles), whereas almost no
instrument response was detected up to 125 µM of the ED mutant
L95AED/S99AED, indicating that the mutations signiﬁcantly
weaken the interaction. We conclude that interface A is the most
relevant for the direct interaction of NS1-ED with TRIM25 CC.
Structure of NS1-FL in complex with TRIM25-CC. While our
experiments established that the effector domain of NS1 is suf-
ﬁcient to form a stable complex with TRIM25, we wondered how
the constraints imposed by the constitutively dimeric RBD within
full-length NS1 might inﬂuence the architecture of the NS1/
TRIM25 assembly. To gain insight into this arrangement we
crystallised a complex between TRIM25-CC and the triple mutant
NS1-FL (R38A/K41A/W187A) and solved the structure by
molecular replacement at 4.26 Å resolution (R/Rfree= 0.27/0.31)
(Table 1). Electron density is observed for two TRIM25 CC
dimers, one complete NS1-FL dimer and two additional NS1-ED
domains (Fig. 3a; Supplementary Fig. 2a).
This structure is the ﬁrst complex between full-length NS1 and
a target protein, and provides crucial insight into the spatial
arrangements of the RBD and ED during target binding. The
RBDs of the NS1 dimer form the canonical homodimeric 6-
helical bundle as observed in the structures of unbound NS1-FL
(PDB: 3F5T and 4OPH), the RBD alone (PDB: 1AIL) and an
RBD/dsRNA complex (PDB: 2ZKO)29,3035,38. Interestingly, the
two NS1 monomers within the homodimer are not symmetrical;
while both monomers align well on the NS1-RBD (RMSD of 0.6
Å), one NS1-ED is shifted towards the stem in relation to the
other by ~17 Å (Fig. 3b, c). The relative arrangement of RBD and
ED seen in this structure is different from previous structures of
NS1-FL, supporting the model that the linker region acts as a
ﬂexible hinge to allow movement of the ED relative to the RBD to
accommodate binding of different substrates (Fig. 3d)29.
The only contacts between TRIM25-CC and NS1-FL are made
by the ED, in agreement with our BLI experiments. Structural
superposition of the NS1-ED/TRIM25-CC complex with that of
NS1-FL/TRIM25-CC shows that interface A, but not interface B,
is present in the full-length complex (RMSD 0.7 Å) (Supplemen-
tary Fig. 2b), conﬁrming its physiological relevance. Our two
structures of NS1/TRIM25-CC complexes clarify the oligomeric
state of TRIM25 upon binding NS1. Previous studies had
suggested that NS1 interferes with CC-mediated dimerisation of
TRIM25 and thereby suppresses activity27,39. However, dimerisa-
tion is unperturbed in both TRIM25/NS1 complexes and instead
the dimeric CC is recognised by two NS1 effector domains at its
distal ends in a symmetrical fashion (Figs. 2 and 3). Furthermore,
a key observation from the NS1-FL/TRIM25-CC structure is that
although the overall architecture of the complex is identical to
that of NS1-ED/TRIM25-CC, the two EDs of a given NS1
homodimer bridge two different TRIM25 dimers that are located
in a perpendicular arrangement in the crystal (Fig. 3a). We
hypothesise that this arrangement highlights the critical role of
the constitutive NS1-RBD dimer in mediating higher order
oligomerization of the NS1–TRIM25 complex, which is likely
important for the proviral function of NS1. These results raise the
question as to how complex formation with NS1 interferes with
the ability of TRIM25 to ubiquitinate RIG-I. To investigate this
further, we aimed to gain further structural insight into the
functional architecture of TRIM25 by determining the position of
the substrate-binding PRYSPRY domain.
The structure of TRIM25 CC-PRYSPRY. The structure of a
human TRIM25 CC-PRYSPRY construct (189–630) was deter-
mined at 3.6 Å resolution (Table 1). The structure was solved by
molecular replacement using the CC structure (PDB:4LTB) and a
de novo determined structure of the human PRYSPRY domain
(residues 434–630) at 2.0 Å resolution (Supplementary Table 1).
The human PRYSPRY domain structure is very similar to that of
mouse TRIM25 (residues 440–634, PDB:4B8E)22 with an RMSD
of 0.64 Å for 189 matched Cα atoms and sequence identity of
81.5% (Supplementary Fig. 3). The CC-PRYSPRY structure has
one and a half CC dimers in the asymmetric unit with a crys-
tallographic twofold completing the second dimer (Supplemen-
tary Fig. 4a–c). Each bow-shaped CC dimer has two PRYSPRY
domains bound towards the ends, maintaining the twofold
Table 1 Data collection and reﬁnement statistics
TRIM25CC/
NS1-ED (PDB:
5NT1)
TRIM25CC/
NS1-FL (PDB:
5NT2)
TRIM25CC-
PRYSPRY
(PDB: 6FLN)
Data collection
Space group C 2 2 2 P 1 P 6122
Cell dimensions
a, b, c (Å) 131.38, 225.23,
146.43
73.26, 76.30,
92.07
89.92, 89.92,
827.09
α, β, γ (°) 90.0, 90.0,
90.0
100.04, 93.71,
111.14
90.0, 90.0,
120.0
Resolution (Å) 48.68–2.82
(2.89–2.82)a
61.51–4.26
(4.33–4.26)a
50–3.60
(3.69–3.60)a
Rmerge 0.092 (1.29)a 0.19 (0.6)a 0.14 (2.4)a
I/σI 14.9 (1.4)a 5.7 (2.5)a 8.2 (0.8)a
Completeness (%) 99.9 (100.0)a 98.6 (97.1)a 99.5 (98.5)a
Redundancy 6.8 (5.7)a 2.6 (2.6)a 5.4 (5.5)a
Reﬁnement
Resolution (Å) 48.68–2.82 61.68–4.26 50–3.60
No. reﬂections 355,400 32,644 131,681
Rwork/ Rfree 0.195/0.224 0.272/0.309 0.287/0.318
No. atoms
Protein 7030 20,802 8861
Water 8 0 0
B-factors
Protein 79.3 122.2 225.2
R.m.s deviations
Bond lengths (Å) 0.006 0.004 0.008
Bond angles (°) 0.8 0.8 1.05
One crystal was used for each structure
aValues in parentheses are for highest-resolution shell
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symmetry (Fig. 4a). The CC structure with the PRYSPRY is only
slightly distorted from that of the CC alone (PDB:4LTB, RMSD
1.16 Å for 169 aligned Cα). The 73-residue long linker (residues
361–433) connecting the CC and PRYSPRY domain is not visible
in the electron density so the exact connectivity is uncertain
(Fig. 4a). The footprint of the PRYSPRY domain on the CC,
which corresponds to a total buried surface area of 1433 Å2, spans
residues 269–287 on helix α1 and residues 320–326 on the
extended connection between α2 and α3, all on the same
monomer (Fig. 4b, Supplementary Fig. 3). These regions contact
PRYSPRY domain surface loops spanning residues 460–464 (L1),
472–476 (L2), 488–494 (L3) and 504–506 (L4) (Fig. 4b, Supple-
mentary Fig. 3). Of note, there are four tyrosines at the interface
(Tyr323, Tyr463, Tyr476 and Tyr488) which are highly conserved
as tyrosine or phenylalanine in mammal and bird TRIM25
(Supplementary Fig. 3).
To gain insight into the dynamics of the TRIM25 CC-
PRYSPRY domain arrangement we performed small-angle X-ray
scattering on the CC-PRYSPRY construct (Supplementary Fig. 5a,
b). In parallel we performed NMR titrations between the separate
CC and PRYSPRY domains (Supplementary Fig. 5c–g). These
experiments show that the interaction between the two domains
is weak in solution but involves the interface observed in the
crystal structure as mutation of Y463S and Y476S weakened the
interaction even further (Supplementary Fig. 5g). The functional
importance of this interface for the correct positioning of the
PRYSPRY to enable substrate ubiquitination is highlighted by the
almost complete loss of RIG-I-2CARD ubiquitination upon
mutation of these residues (Fig. 4c) although the overall fold of
the PRYSPRY domain remains intact (Supplementary Fig. 5f).
Taken together, these experiments suggest that in the absence of
other components of the system, the PRYSPRY domain is in a
dynamic equilibrium between a bound state and a constrained
diffusing state tethered to the CC by the ﬂexible linker, in
agreement with recent results40, but that the bound state is
important to enable substrate ubiquitination.
Superposition of the NS1-ED and PRYSPRY-bound CC
structures shows that the two domains bind at the same position
near the end of the CC but on opposite sides such that they would
sterically clash only minimally (Fig. 4d). NS1-ED binds mainly to
the region spanning residues 212–229 of helix α1 of one
monomer but also to residues 274–277 of helix α1 from the
other monomer. The PRYSPRY domain only binds to helix α1 of
the second monomer (residues 269–287) (Supplementary Fig. 3).
However, a key observation is that both domains bind to the
extended region between helices α2 and α3 (residues 316–331)
and strikingly, binding of NS1-ED necessitates a considerable
distortion of this region away from its structure in the PRYSPRY-
bound or PRYSPRY-unbound CC (Fig. 4d). Thus, while the
binding sites of the PRYSPRY domain and NS1-ED are on
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opposite sides of the CC, both contact the α2 and α3 linker and
simultaneous binding is impossible.
Inhibition of TRIM25 activity by NS1. To test if the changes
brought upon by NS1 binding interfere with the correct juxta-
position of the E2~ubiquitin-binding RING and substrate-
binding PRYSPRY domains and hence substrate ubiquitination,
we analysed TRIM25-mediated RIG-I ubiquitination in cells. In
the absence of NS1, overexpression of TRIM25 FL induced a
signiﬁcant increase in RIG-I-2CARD ubiquitination, which was
severely suppressed in the presence of NS1 WT (Fig. 5a). Muta-
tion of R38A, K41A or W187A in NS1 did not affect the ability of
NS1 to suppress RIG-I ubiquitination, in accordance with our
binding studies (Figs. 1c and 5a). Interestingly, combining
mutation Y89A, with mutation of L95A/S99A, which severely
weakened complex formation between TRIM25 and the isolated
ED, had only a minor effect on the ability of NS1-FL to suppress
RIG-I ubiquitination (Figs. 2c and 5a). This observation strongly
suggests that FL NS1-mediated higher order oligomerization of
TRIM25, and potentially higher order self-association of NS1, are
important factors in the mechanism of suppression and can
overcome a weakened direct NS1–TRIM25 interaction due to
avidity effects.
Given that NS1 does not interfere with CC-mediated
dimerisation of TRIM25 and instead prevents the correct
positioning of the PRYSPRY domain on the CC required for
substrate ubiquitination, we wondered what the effect of NS1
might be on free K63-linked poly-ubiquitin chain synthesis. We
have previously shown that the RING domains of TRIM25 need
to be dimeric for catalytic activity and have proposed a model in
which RING dimerisation may occur in an intramolecular
fashion23. To examine whether NS1 binding to TRIM25 affects
catalytic activity we performed UbcH5C~Ub discharge assays
with recombinant TRIM25-FL in the presence of increasing
concentrations of different NS1 constructs to assess the substrate-
independent E3 ligase activity of TRIM25 (Supplementary Fig. 6).
These experiments show that TRIM25-mediated discharge of
UbcH5C~Ub remains unaltered in the presence of all NS1
proteins tested, suggesting that NS1 binding does not interfere
with the catalytic activity of TRIM25 per se. To further validate
this observation, we performed ubiquitination assays with
heterodimeric UBE2N/UBE2V1 that catalyses the formation of
unanchored K63-linked poly-ubiquitin chains in the absence of
RIG-I (Fig. 5b and Supplementary Fig. 6c). These experiments
clearly show that poly-ubiquitin chain formation is also
unaffected by the presence of NS1. Taken together, these
experiments demonstrate that the intrinsic catalytic activity of
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TRIM25 is not suppressed even in the presence of high
concentrations of NS1.
Next, we tested how the loss of RIG-I ubiquitination affected
signalling downstream of RIG-I (Fig. 5c). Expression of the
tandem CARDs of RIG-I is sufﬁcient to induce spontaneous
activation of the RIG-I/MAVS pathway, even in the absence of an
RNA ligand11. Indeed, expression of RIG-I-2CARD, in combina-
tion with TRIM25, triggered type I IFN production, as measured
using a reporter plasmid expressing the ﬁreﬂy luciferase gene
under the control of the IFN-β promoter (Fig. 5c). WT NS1
potently suppressed RIG-I-2CARD-induced expression of the
IFN-β promoter-regulated luciferase reporter, as shown pre-
viously27 (Fig. 5c). This suppression activity was not affected by
mutations R38A, K41A or W187A in accordance with our
binding and ubiquitination assays. Similarly, the L95A/S99A/
Y89A mutant, which only had a minor effect on RIG-I
ubiquitination in FL NS1 (Fig. 5a), is still capable of inhibiting
the interferon response. This further indicates that even a low
afﬁnity direct interaction between NS1 and TRIM25 is sufﬁcient
for suppression due to avidity effects through higher order
oligomerization. In summary, our structures and ubiquitination
assays show that NS1 binding to TRIM25 inhibits RIG-I
ubiquitination by steric effects, while leaving the ability of
TRIM25 to form unattached K63 chains intact.
Discussion
RIG-I is an intracellular PRR that plays a key role in the innate
immune response against a variety of viruses. Recognition of viral
RNA by RIG-I initiates a signalling cascade that culminates in the
production of IFNs and proinﬂammatory cytokines. Ubiquitina-
tion of RIG-I by TRIM25 is crucial for the activation of the RIG-
I/MAVS signalling pathway establishing TRIM25 as a key player
in antiviral immunity. Conversely, viruses have evolved intricate
mechanisms to interfere with the host immune response, one of
which is the sequestration of TRIM25 by inﬂuenza A virus NS1.
This interaction was originally suggested to suppress RIG-I ubi-
quitination and IFN production, although a recent study
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proposed instead that the physiologically important consequence
of TRIM25/NS1 complex formation was prevention of vRNP-
binding by TRIM2527,36. Both the RBD and ED of NS1 were
suggested to be required for TRIM25 recognition and suppression
of its E3 ligase activity27. Here we show by quantitative analysis of
the TRIM25/NS1 interaction that the ED is sufﬁcient to form a
stable complex (Fig. 1c). To understand NS1-mediated inhibition
of TRIM25 activity on a molecular level we have determined
crystal structures of the CC domain of TRIM25 in complex with
NS1-FL and the isolated ED, and of a TRIM25 CC-PRYSPRY
fragment, which includes the RIG-I-recognition domain of
TRIM25. These structures establish that NS1 binding does not
inhibit TRIM25 function by interfering with the CC-mediated
dimerisation of TRIM25. Instead, two NS1 molecules bind sym-
metrically to each monomer of the dimeric CC (Figs. 2 and 3).
Moreover, a structural comparison between the TRIM25/NS1
complex and the TRIM25 CC-PRYSPRY fragment reveals that
NS1 and the PRYSPRY domain bind in a mutually exclusive
fashion to overlapping sites on the CC (Fig. 4d). Using interface
disrupting mutations we show that PRYSPRY domain binding to
the CC is required for RIG-I CARD ubiquitination (Fig. 4c).
Thus, NS1 competition for the CC provides a mechanism for NS1
interference with RIG-I ubiquitination and downstream signal-
ling. It is unlikely that NS1 binding interferes with substrate
recognition per se: the PRYSPRY domain is not contacted by NS1
and it has previously been shown that NS1 does not inhibit
TRIM25/RIG-I complex formation27,39. Instead, our data are
consistent with a model in which TRIM25/NS1 complex forma-
tion prevents the correct functional juxtaposition of the RING
and PRYSPRY domains required to bring the substrate into close
proximity with the E2~Ub conjugate to promote ubiquitin
transfer (Fig. 6).
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Intriguingly, structure-based mutations in NS1 (L95A/S99A/
Y89A) that severely weaken the interaction between the isolated
NS1-ED and TRIM25-CC in vitro still suppress RIG-I ubiquiti-
nation in cells (Fig. 5a). In conjunction with our observation that
NS1-FL connects two different TRIM25 dimers and the natural
tendency of wild-type NS1 to form higher order oligomers and
aggregates, this suggests that a productive TRIM25–NS1 inter-
action requires two components: a direct protein–protein inter-
face to provide speciﬁcity as determined in our structures, and the
propensity of NS1 to induce the formation of large TRIM25/NS1
assemblies. In accordance with the ubiquitination assays, all
mutants signiﬁcantly suppressed RIG-I-induced IFN expression.
This includes the NS1 R38A/K41A mutation located in the RBD,
which was previously suggested to abrogate the inhibitory effect
of NS1 on RIG-I signalling27. This mutation has been shown to
interfere with RNA-binding, which is required for NS1 function
during inﬂuenza virus infection41,42. However, our structures
show that these residues do not contact TRIM25 directly, con-
sistent with our observation that they do not affect ubiquitination
of the tandem CARDs of RIG-I or IFN production in cells.
Nevertheless, the R38A/K41A mutation suppresses NS1 self-
association, at least partially (Fig. 1b)29,30, and we speculate that
depending on experimental conditions this may result in the
apparent loss of RIG-I ubiquitination as observed previously27.
Further studies will be required to fully understand the precise
role of NS1 self-association in the inhibition of RIG-I ubiquiti-
nation by TRIM25 and the suppression of a host immune
response. Interestingly, although binding of NS1 strongly sup-
presses substrate ubiquitination, it has no effect on the ability of
TRIM25 to synthesise unanchored K63-linked poly-ubiquitin
chains. Given that overexpression of NS1 suppresses IFN pro-
duction in luciferase reporter assays, this implies that unanchored
K63 chains are not sufﬁcient to activate the RIG-I/MAVS path-
way under these conditions.
Comparison of our NS1/TRIM25 structure with the NS1-ED/
p85β structure (PDB: 3L4Q) reveals remarkable similarities in the
manner in which the NS1-ED recognises its targets43,44. p85β, a
regulatory subunit of the phosphoinositide 3-kinase (PI3K)
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complex, is a multi-domain protein containing a rigid elongated
CC domain (β-iSH2) which is targeted by IAV NS1 to stimulate
PI3K activity. Intriguingly, NS1-ED binds β-iSH2 through the
same interface observed in our complex with TRIM25-CC,
involving the short NS1 α-helix comprising residues 95–99 that
packs against the target CC region (Supplementary Fig.7). The
fact that NS1 uses the same surface to bind similar structural
features in diverse target proteins suggests one mechanism by
which viral proteins can evolve multi-functionality. However, the
overlap in binding surfaces used to target different host proteins
also implies that the analysis of NS1 mutations in recombinant
virus assays is more complicated than previously assumed as a
given mutation may affect interaction of NS1 with multiple tar-
gets and hence affect multiple host activities. More NS1/host
protein structures are required to fully appreciate how frequently
viral proteins use overlapping binding surfaces to target different
host proteins.
At present, no structure of a full-length TRIM protein is
available that could provide molecular insight into the overall
arrangement of the E3/E2-Ub conjugate/substrate complex
during the ubiquitin transfer reaction. However, structural
characterisation of the CC domains of a number of TRIM
family proteins have shown that they all form anti-parallel
dimers of ~170 Å in length, which based on sequence con-
servation likely constitutes a general property of this protein
family37 (Supplementary Fig. 8). The crystal structure of a CC-
PRYSPRY fragment of TRIM20 shows that the two PRYSPRY
domains are positioned close to the dimer twofold axis with a
centre of mass separation of only ~45 Å (PDB:4CG4). This is a
consequence of the short helical linker between the end of the
helical CC and the PRYSPRY domain in TRIM20 (Supple-
mentary Fig. 8b). Even so, the linker can bend leading to some
variability in the position of the PRYSPRY domain, which does
not itself make any stabilising contact with the CC. In contrast,
the TRIM25 linker is much longer, although of variable length
and sequence between species, and is unstructured, allowing the
PRYSPRY domain to form a transient interaction nearer the CC
ends (centre of mass separation ~110 Å) that is important for
substrate ubiquitination (Fig. 4a). About half of all TRIM family
proteins contain a PRYSPRY domain, each adapted to recognise
a different substrate. The observed variety in linker ﬂexibility
and PRYSPRY position may be important to accommodate
substrates of different sizes and position them in the correct
orientation to facilitate their ubiquitination. Although no
structure of the TRIM25 tandem B-boxes exists, the structure of
the TRIM5α CC with its single B-box indicates their probable
location (Supplementary Fig. 8c). Finally, superposition of the
TRIM25 CC-PRYSPRY structure with the TRIM21 PRYSPRY-
Fc structure suggests that the equivalent, putative substrate-
binding surface of the TRIM25 PRYSPRY domain would
remain accessible when the PRYSPRY domain is bound to the
CC (Supplementary Fig. 8d), although recently it was proposed
that a cryptic second site on the PRYSPRY domain would also
bind the RIG-I CARDs40.
In this context it is interesting to note that a number of pro-
teins have been identiﬁed that interact with the CC region to
regulate TRIM protein activity. Some of these are viral proteins
that suppress TRIM activity in order to interfere with an antiviral
response. Examples are IAV NS1 as described in this study or the
immediate-early protein IE1 from herpes virus human cytome-
galovirus (HCMV), which antagonises the antiviral activity of
TRIM19/PML nuclear bodies45,46. Others like MAGE (melanoma
antigen genes) proteins have been shown to bind the CC domain
of TRIM28 to enhance ligase activity and possibly contribute to
substrate targeting47,48. Based on these observations we hypo-
thesise that the CC domain of TRIM ligases might act as a more
general protein interaction platform that is exploited by patho-
gens as well as oncogene products to regulate ligase activity and/
or redirect substrate speciﬁcity.
Methods
Protein production and puriﬁcation. Cloning, expression and puriﬁcation of His-
Ube1, UBE2D3 (UbcH5c), UBE2N (Ubc13), UBE2V1 (UEV1) and M1C-ubiquitin
have been described before49,50.
NS1 (strain A/Puerto Rico/8/1934, UniProt P03496) constructs NS1-RBD
(1–73), NS1-ED (79–230) and NS1 mutants NS1-FL (W187A), NS1-FL (R38A/
K41A/W187A), NS1-FL (R38A/K41A), NS1-ED (L95A/S99A), NS1-ED (R140A)
were cloned into pET-47b (Merck Millipore) to produce cleavable His6-tagged
fusion proteins. TRIM25-CC (189-379) (UniProt Q14258) was inserted into pET-
52b (Merck Millipore) to produce cleavable Strep-Tag II fusion protein. All
mutations were introduced by site-directed mutagenesis and veriﬁed by DNA
sequencing. All proteins were expressed in BL21 (DE3) E.coli cells, induced at 0.6
OD600 with 150 µM isopropyl b-D-1-thiogalactopyranoside (IPTG) and incubated
at 18 °C for 16 h. Proteins were puriﬁed by afﬁnity chromatography, followed by
ion-exchange chromatography if necessary (after removal of His, GST or Strep-II
tags by HRV 3 C protease) and size-exclusion chromatography (SEC).
Human TRIM25 PRYSPRY (residues 434–630) was cloned from a synthetic
gene (GeneArt, Regensburg, Germany) into pFastBacHtb vector for expression in
the baculovirus system following standard procedures (Bac-to-Bac manual,
Invitrogen). The protein was expressed in HiFive insect cells in Express Five SFM
medium (ThermoFisher Scientiﬁc, B85502) supplemented with glutamine
according to standard protocols. For puriﬁcation, a cell pellet was resuspended in
buffer A (20 mM HEPES pH 7.5, 150 mM NaCl, 20 mM imidazole and 5 mM beta-
mercapto-ethanol) and cells were lysed by sonication. Cleared lysate was applied
onto a Nickel NTA superﬂow column (Qiagen). The column was washed with
buffer A containing 1M NaCl and the protein was eluted in buffer A supplemented
with 300 mM imidazole. The His-tag was cleaved by incubation with Tobacco Etch
Virus (TEV) protease overnight at 4 °C. The protein was dialysed into buffer A and
TEV protease and residual his-tagged protein were removed by passage through a
Ni-NTA column. Residual aggregates were removed in a ﬁnal SEC step on a
Superdex 200(10/300) column (GE Healthcare) in a buffer containing 20 mM
HEPES pH 7.5, 100 mM NaCl, 20 mM imidazole and 5 mM beta-mercapto-
ethanol. The protein was concentrated using an AMICON spin concentrator.
Human TRIM25 CC-PRYSPRY domain (residues 189–630) was cloned from a
synthetic gene (GeneArt, Regensburg, Germany) into pFastBacHtb vector (in
between NcoI and HindIII restriction sites) for expression in the baculovirus
system (Bac-to-Bac manual, Invitrogen). The protein was expressed in HiFive
insect cells in Express Five SFM medium (Invitrogen) supplemented with
glutamine according to standard protocols. A cell pellet was resuspended in buffer
A (50 mM HEPES pH 7.5, 300 mM NaCl, 20 mM imidazole, 5% glycerol and 10
mM beta-mercapto-ethanol) and cells were lysed by sonication. Cleared lysate was
applied onto a Nickel NTA resin (His60 NI Clontech). The column was washed
with buffer A containing 1 M NaCl and the protein was eluted in buffer A
supplemented with 300 mM imidazole. The His-tag was cleaved by incubation with
TEV protease overnight at 4 °C. The protein was dialysed into buffer A (except
NaCl was reduced at 120 mM) and TEV protease and residual his-tagged protein
were removed by passage through a Ni-NTA column. Cleaved protein was further
puriﬁed by cation exchange chromatography (HiTrap SP HP, GE Healthcare) a
ﬁnal SEC step on a Superdex 200 Increase (10/300 GL) column (GE healthcare) in
a buffer containing 20 mM HEPES pH 7.5, 100 mM NaCl and 500 μM TCEP.
TRIM25 coiled-coil-PRY-SPRY was identiﬁed as a dimer (elution volume Ve= 12
ml) conﬁrmed by MALLS (data not shown). 1 mM TCEP was added to the sample
and the protein was concentrated using an AMICON spin concentrator.
Full-length TRIM25 was inserted into pIEX-Bac3 vector (Merck Millipore) with
an N-terminal His10-tag and an HRV 3 C protease cleavage site using ligation
independent cloning (LIC). Protein was expressed in SF9 insect cells
(ThermoFisher Scientiﬁc 1149015), using a protocol described previously51. Cells
from 2.1 L of culture were resuspended in lysis buffer (100 mM HEPES, pH 7.0,
500 mM NaCl, 5% (v/v) glycerol, 1 mM TCEP, 20 mM Imidazole, 10 mM MgCl2),
supplemented with 1 mM PMSF, 2 tablets of EDTA-free protease inhibitor cocktail
tablets (Roche), and 25 units/ml Benzonase nuclease (Sigma). Cells were lysed by
sonication and debris was removed by centrifugation (55,000 × g for 45 min at 4 °
C). The supernatant was incubated with 5 ml of Talon superﬂow resin (GE
Healthcare) for 3 h on a rocker at 4 °C. The resin was washed extensively with wash
buffer (100 mM HEPES, pH 7.0, 500 mM NaCl, 10% (v/v) glycerol, 1 mM TCEP,
40 mM Imidazole). Bound protein was eluted in wash buffer containing 300 mM
Imidazole in a total volume of 5 ml and incubated with HRV-3C to remove the
His10-tag. The protein was puriﬁed to homogeneity on a HiLoad 16/600 Superdex
200 gel ﬁltration column (GE Healthcare) in size-exclusion buffer (50 mM HEPES,
pH 7.0, 100 mM NaCl, 1 mM DTT). Protein-containing fractions were diluted in
buffer containing 50 mM HEPES pH 7.0, 50 mM NaCl, 1 mM DTT and applied to
a 1 ml SP FF IEX column (GE Healthcare) as a means of protein concentration.
Protein was eluted in buffer containing 50 mM HEPES pH 7.0, 300 mM NaCl, 1
mM DTT and ﬂash-frozen in liquid nitrogen and stored at –80 °C.
For stable isotope labelling (15N, 13C, and 2H) the human PRYSPRY domain
(residues 439-630) was cloned into pETm22 and co-expressed with chaperones
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KJE, ClpB and GroELS in E. coli BL21(DE3). The protein was puriﬁed using
Ni-NTA afﬁnity chromatography, prior to cleaving the tag, using 3C protease and
removal of the tag by ion-exchange chromatography.
Protein molecular mass was veriﬁed by electrospray ionisation mass
spectrometry. The fold of wild-type and mutant proteins was analysed by circular
dichroism spectroscopy. Protein concentrations were determined by UV
absorption at 280 nm using calculated extinction coefﬁcients. Bovine mono-
ubiquitin was purchased from Sigma and further puriﬁed by SEC.
Production of the UbcH5c~Ub thioester. M1C-ubiquitin was labelled with Atto
647 N maleimide (Sigma) as described for Cy5 labelling50. UbcH5c~UbAtto con-
jugate were synthesised as previously described52. Brieﬂy, His-Ube1 (1 µM),
UbcH5c (250 µM), Atto 647N-Ub (UbAtto) (500 µM) and ATP (3 mM) (Sigma)
were incubated for 60 min at 25 °C. The UbcH5c~UbAtto thioester-linked conjugate
was puriﬁed by SEC using a HiLoad 16/60 Sephadex 75 gel ﬁltration column (GE
Healthcare) pre-equilibrated in 50 mM HEPES pH 7.5, 150 mM NaCl and ﬂash-
frozen in liquid nitrogen.
In vitro ubiquitination assays. Ubiquitin discharge assays with pre-charged
UbcH5c~UbAtto were performed as previously described23. Brieﬂy, 1 μM UbcH5-
c~UbAtto and 1 μM TRIM25-FL were incubated with 1 or 10 or 100 µM of different
NS1 constructs/mutants (NS1-ED, NS1-FL (R38A/K41A/W187A or W187A)) in
buffer containing 50 mM HEPES pH 7.5, 150 mM NaCl and 20 mM L-Lysine.
Reactions were incubated at 25 °C and quenched with 2× SDS sample buffer at 0, 5,
15 min. Samples were resolved by SDS-PAGE and gels were scanned at 635 nm
with a Typhoon FLA 9500 and analysed using ImageQuant (GE Healthcare). Gels
were subsequently stained with InstantBlue for total protein content. Ubiquitina-
tion assays with UBE2N/UBE2V1 were performed with 0.5 μM His-Ube1, 2.5 μM
of each E2, 1 μM TRIM25-FL, 1, 10 or 100 µM of NS1 constructs/mutants (NS1-
ED, NS1-FL (R38A/K41A/W187A) or NS1-FL (W187A)), 50 μM ubiquitin and 0.5
μM UbAtto in buffer containing 50 mM HEPES pH 7.5, 150 mM NaCl, 20 mM
MgCl2 and supplemented with 10 mM ATP. Gels were scanned and subsequently
stained with InstantBlue. Experiments were performed in triplicate and repre-
sentative images are shown.
Cell culture and transfection. HEK293T cells (supplied by ECACC, authenticated
by STR proﬁling and species ID, tested monthly for mycoplasma contamination)
were cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM; Gibco, Thermo-
Fisher Scientiﬁc) supplemented with 10% heat-inactivated foetal calf serum
(Autogen Bioclear UK, Ltd), 2 mM glutamine and 100 U/ml penicillin/strepto-
mycin (Gibco, ThermoFisher Scientiﬁc) at 10% CO2 at 37 °C. 3FLAG-tagged and
GST-tagged human RIG-I tandem CARDs (UniProt O95786), NS1 and mutants
(strain A/Puerto Rico/8/1934 H1N1) were cloned into pcDNA3.1 and veriﬁed by
Sanger sequencing. pCMV-HA-TRIM25 was purchased from the MRC-PPU,
Dundee (DU 12451). Cells were transfected using Lipofectamine 2000 (Thermo-
Fisher) according to manufacturer’s instructions.
RIG-I ubiquitination assays. HEK293T cells were transfected with 3FLAG-
2CARD, TRIM25, and NS1 in a 6-well plate. Twenty-four to 48 h post-transfection,
cells were washed once in cold PBS and lysed in plates using an NP-40-based lysis
buffer [0.5% NP-40, 150 mM NaCl, 50 mM Tris pH 7.5, 5 mM MgCl2, protease
inhibitors (EDTA-free mini tablets, Pierce)] for 45 min at 4 °C. Cell lysates were
cleared by centrifugation (14,500 × g, 15 min, 4 °C). Lysates were subjected to
FLAG immunoprecipitation using FLAG M2 agarose beads (Sigma Aldrich) for 2 h
at 4 °C. Immunoprecipitates were washed three times in lysis buffer and resolved
on 4–12% NuPAGE Bis-Tris precast gels (Invitrogen), transferred to PVDF
membrane using the iBlot semi-dry transfer system (Invitrogen), blocked in either
1% non-fat dried milk or 2% BSA (Anti-Ubiquitin) in TBS-T (TBS, 0.1% Tween-
20), and incubated with the relevant primary antibodies: Anti-FLAG HRP (A8592,
Sigma Aldrich, 1:10,000 dilution), Anti-TRIM25 HRP (ab200788, AbCam, 1:5000
dilution), Anti-NS1 HRP (NS1-23–1) (sc130568, Santa-Cruz Biotechnology, 1:500
dilution), Anti-Ubiquitin HRP (PD41) (sc8017, Santa-Cruz Biotechnology, 1:500
dilution). Uncropped scans of western blots are shown in Supplementary Fig. 9.
Luciferase reporter assay. 1.25 × 105 HEK293 cells/well were plated in 24-well
plates, and transfected the next day with the following constructs: GST-2CARD
(25 ng), TRIM25 (10 ng), and NS1 (25/50/100 ng) using empty pcDNA3.1 to adjust
the total amount of transfected DNA to 135 ng/well. After 24 h, cells were trans-
fected with 125 ng of p125-Luc, encoding a Fireﬂy luciferase reporter gene under
the control of the IFN-β promotor (gift from T. Fujita, Kyoto University, Japan)
and 25 ng pRL-TK (Promega) using Lipofectamine 2000. Luciferase activity was
measured 18–20 h later using the dual-luciferase assay reporter system (Promega).
Fireﬂy luciferase values were divided by Renilla luciferase values to normalise for
transfection efﬁciency. All data are shown as fold increase relative to mock-
transfected cells.
SEC–MALLS. Analytical SEC-coupled to multi angle laser light scattering (MALLS)
proﬁles were recorded at 16 angles using a DAWN-HELEOS-II laser photometer
(Wyatt Technology) and differential refractometer (Optilab TrEX) equipped with a
Peltier temperature-regulated ﬂow cell maintained at 25 °C (Wyatt Technology).
Samples of puriﬁed proteins at different concentrations (100 μl volume) were
applied to a Superdex 200 10/300 GL column (GE Healthcare) equilibrated with 50
mM HEPES pH 7.5, 150 mM NaCl, 0.5 mM TCEP and 3mM NaN3 at a ﬂowrate of
0.5 ml/min. The data were analysed using ASTRA 6.1.
Binding studies by biolayer interferometry. The binding of NS1 constructs to
immobilised TRIM25-CC was measured on an Octet RED biolayer interferometer
(Pall ForteBio Corp., Menlo Park, CA, USA). His-tagged TRIM25-CC was
immobilised on Ni-NTA biosensors (Pall ForteBio Corp., Menlo Park, CA, USA)
using a concentration of ~12 μg/ml. The binding of the NS1 constructs (at 1–55
µM) to immobilised TRIM25-CC was measured at 25 °C with a 200 s association
step followed by a 200 s dissociation step. The buffer was 50 mM HEPES (pH 7.5),
150 mM NaCl, 1 mM DTT and 0.005% Tween-20. The equilibrium dissociation
constant was determined by analysing the variation of the response with construct
concentration using non-linear least-squares methods and assuming a simple 1:1
binding model. Experiments were performed at least in triplicate.
Crystallisation. NS1-ED (9 mg/ml) was mixed with TRIM25-CC (10 mg/ml) at a
1:1 molar ratio and crystallisation trials set up using an Oryx crystallisation robot.
Initial hits were optimised by hanging drop vapour diffusion at 18 °C with a
reservoir solution containing 100 mM Tris pH 8.5, 25 % PEG 600 and 200 mM
sodium citrate and reaching full size (0.7 mm) after 5 days. Crystals were ﬂash-
frozen in the reservoir solution containing 30% PEG 600. NS1-FL (R38A/K41A/
W187A) (8 mg/ml) was mixed with TRIM25-CC (10 mg/ml) at a 1:1 molar ratio
and crystallisation trials set up using an Oryx crystallisation robot. Clustered plates
appeared within 3 days and were used for seeding in order to optimise the size and
morphology of the crystals. Single cubic crystals appeared within 3 days in a seeded
drop (0.02 μl seed stock+ 0.1 μl protein mixture+ 0.1 μl reservoir solution) with a
reservoir solution containing 100 mM sodium citrate pH 6.5 and 24% PEG 3350.
Crystals were cryoprotected in the reservoir solution containing 25% glycerol and
ﬂash-frozen.
Human TRIM25 PRYSRPY domain was crystallised by vapour diffusion in
sitting drops by mixing 15 mg/ml protein in a 1:1 ratio with reservoir solution
containing 0.1 M bis-Tris pH 6.5 and 2M ammonium sulphate. Crystals grew in
2 days and were cryoprotected by soaking for 30 s in 0.08M bis-Tris pH 6.5 and
1.6 M ammonium sulphate and 20% glycerol.
Human TRIM25 CC-PRYSPRY was crystallised by vapour diffusion in sitting
drop by mixing 10 mg/ml dimer in a 1:1 ratio with reservoir solution. 576 different
conditions were initially screened robotically at 20 °C and reﬁned in 24-well
hanging drop crystallisation plates by mixing 1 μl protein with 0.5 μl reservoir
solution. Large dagger-shaped crystals were obtained after 5 days. The best crystals
grew in mother liquor containing 0.2 M sodium formate, 14% PEG 3350 and 0.1 M
bis-Tris pH 6.5. 15% glycerol was added to cryo-protect.
Data collection and structure determination. Data for both NS1-ED/TRIM25-
CC and NS1-FL (R83A/K41/W187A)/TRIM25-CC crystals were collected on
beamline IO4 (λ= 0.9795 Å) at the Diamond Light Source (Oxford, UK) and
processed using XDS53 and autoPROC54, respectively. Both structures were solved
by molecular replacement (MR) using 3O9T as a search molecule for NS1-ED,
1AIL for NS1-RBD and 4LTB for TRIM25-CC in Phaser55. For the NS1-ED/
TRIM25-CC structure, we ﬁrst identiﬁed the MR solution for TRIM25-CC, which
was ﬁxed as a partial solution in order to locate NS1-ED. The solution for the three
copies of TRIM25-CC and three copies of NS1-ED in the asymmetric unit was
unambiguously identiﬁed with a translational function Z-score (TFZ) of 19.8. For
the NS1-FL (R38A/K41A/W187A)/TRIM25-CC structure, we ﬁrst identiﬁed the
partial molecular replacement solution containing two complexes of NS1-ED/
TRIM25-CC in the asymmetric unit (TFZ= 16.5). Subsequently, this solution was
ﬁxed and two out of four molecules of NS1-RBD were located with a TFZ score of
18.6. Models were iteratively improved by manual building in Coot and reﬁned
using REFMAC5 and Phenix56,57. All structural ﬁgures were prepared in PyMOL.
Protein interfaces were calculated using PISA58. Coordinates and structure factors
were deposited in the Protein Data Bank under accession codes 5NT1 and 5NT2.
For phasing of the human TRIM25 PRYSRPY domain, a crystal grown under
native conditions was transferred into the reservoir solution supplemented with 2
mM ethyl-mercuric chloride and soaked for 8 h before cryo-protection and
freezing. Diffraction measurements were made at the ESRF on beamlines ID23-2
(native) and ID14-EH4 (Hg derivative) and processed with XDS53. The structure
was solved by single isomorphous replacement with anomalous scattering. Six
mercury sites were found and reﬁned with SHARP59. The resultant map was
improved by threefold non-crystallographic averaging and an initial model was
built by ARP/WARP60. Subsequent reﬁnement was done with REFMAC57. Data
collection and reﬁnement statistics are listed in Supplementary Table 1.
Data of human TRIM25 CC-PRYSPRY crystals were collected on ESRF
beamline ID29, which was able to nicely resolve the diffraction spots along the very
long c*-axis (1/827 Å−1), and processed with XDS53. The structure was solved by
molecular replacement using PHASER55 and the known structure of the hTRIM25
coiled-coil (PDB:4LTB)21 and the hTRIM25 PRYSPRY domain described here.
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Reﬁnement was performed with REFMAC57 and BUSTER. Data collection and
reﬁnement statistics are listed in Table 1. An example of the map-sharpened
electron density is in Supplementary Figure 4A. There are one and a half coiled-coil
dimers in the asymmetric unit with a crystallographic twofold completing the
second dimer and the molecules form a three-dimensional network throughout the
crystal (Supplementary Figure 4B).
Small-angle X-ray scattering data collection and analysis. Small-angle X-ray
scattering (SAXS) measurements were carried out at the BM29 beamline at the
ESRF, Grenoble61. The CC-PRYSPRY sample was measured in NMR buffer (20
mM Na2HPO4 pH 6.5, 150 mM NaCl, 2 mM DTT) at four different concentrations
ranging between 1.0 and 20 mg/ml at 300 K. Ten frames with 1 s exposure time per
frame were recorded for each sample and buffer using an X-ray wavelength of
0.992 Å. Measurements were performed in ﬂow mode, by pushing the sample
through a capillary at constant ﬂowrate to minimise radiation damage. Frames
showing radiation damage were removed before data analysis. For SAXS data
collection and processing, the dedicated beamline software BsxCuBE was used in
an automated fashion. The one-dimensional scattering intensities of samples and
buffers were expressed as a function of the modulus of the scattering vector Q=
(4π/λ)sin θ with 2θ being the scattering angle and λ the X-ray wavelength. Buffer
intensities were subtracted from samples using the software PRIMUS62. The radii
of gyration Rg of all samples were extracted by the Guinier approximation with the
same programme and also together with Dmax were calculated from pairwise dis-
tribution functions using GNOM63. All statistics are summarised according to
Trewhella et al.64 in Supplementary Table 2.
PRYSPRY-CC models to ﬁt against the experimental data were generated using
a restrained MD/SA protocol implemented in CNS65 as previously described66. In
short, a template structure with CC and PRYSPRY domain connected with the 73-
residue linker was generated. Then the linker (residues 361–433) was kept
disordered by random rotation of the φ and ψ backbone angles during structure
calculations. The resulting structures were subsequently minimised by a 3-step
Cartesian dynamics simulated annealing protocol with 40,000 high-temperature
(20,000 K) steps followed by two cooling phases of 4000 steps (2000 to 1000 K and
1000 K to 50 K). In a ﬁrst calculation of 5000 structures, the interface between the
CC and PRYSPRY domain was kept rigid but the linker was allowed to move freely.
During the second calculation only one PRYSPRY domain was ﬁxed to the CC
domain, whereas the other and the linker were allowed to move freely. The third
calculation allowed free movement of both PRYSPRY domains including the linker.
Each pool of 5000 structures was ﬁtted against SAXS data using CRYSOL67.
NMR data collection and analysis. NMR spectra were acquired at 298 K on a
Bruker Avance III NMR spectrometer equipped with a cryogenic triple resonance
gradient probe head at a magnetic ﬁeld strength corresponding to a proton Larmor
frequency of 800MHz. Samples were measured at concentrations ranging between
0.1 and 0.5 mM in 20 mM Na2HPO4, 150 mM NaCl, 0.5 mM TCEP at pH 6.5. All
spectra were processed with NMRPipe68 and analysed using Sparky69, CCPNMR70
and CARA (http://cara.nmr.ch). For backbone resonance assignments of the
PRYSPRY domain, HNCACB, CBCA(CO)NH and HNCA spectra were recorded.
Backbone resonance assignment was obtained to a completion of 95% (175 out of
184 HN-N resonances). Backbone resonance assignments of the Y463S/Y476S
double mutant was possible by tracing the peak shifts. Ambiguous peak positions
were left out of the analysis. Peak intensities for NMR titrations were calculated in
SPARKY by keeping the linewidth constant during ﬁtting and manually corrected
for dilution during the titration.
Data availability. Atomic coordinates and structure factors have been deposited in
the Protein Data Bank under accession codes 5TN1 for the TRIM25-CC/NS1-ED
complex, 5NT2 for the TRIM25-CC/NS1-FL complex, 6FLM for the TRIM25
PRYSPRY domain and 6FLN for the TRIM25 CC-PRYSPRY fragment. Backbone
assignments of the TRIM25-PRYSPRY domain have been deposited at the Biolo-
gical Magnetic Resonance Bank (BMRB) under accession code 27381. Other data
are available from the corresponding author upon request.
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